Title: Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
Authors: Wilding, J P H ×
Charpentier, G
Hollander, P
González-Gálvez, G
Mathieu, Chantal
Vercruysse, F
Usiskin, K
Law, G
Black, S
Canovatchel, W
Meininger, G #
Issue Date: Dec-2013
Publisher: Medicom International
Series Title: International Journal of Clinical Practice vol:67 issue:12 pages:1267-82
Article number: 10.1111/ijcp.12322
Abstract: Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of type 2 diabetes mellitus (T2DM). This randomised, double-blind, placebo-controlled, Phase 3 study evaluated the efficacy and safety of canagliflozin as an add-on to metformin plus sulphonylurea in patients with T2DM.
ISSN: 1368-5031
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Clinical and Experimental Endocrinology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science